UCBJY News and Press, UCB S.A. ADR From 01/08/23

Summary Immunovant is developing a similar drug to argenx, but at 10% of argenx’s valuation, offering a good option value and a hedge against owning argenx. Immunovant has a new generation anti-FcRn IMVT-1402, and recent pre-clinical data showed that it does not impact albumin le...

UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review PR Newswire Biologic License Application (BLA) designated Priority Review by FDA and seeks approval for rozanolixizumab for the treatment...

UCB ( OTCPK:UCBJY ) ( OTCPK:UCBJF ) said its medicine bimekizumab met the main goal of two phase three studies to treat a skin condition called hidradenitis suppurativa The studies dubbed BE HEARD I and BE HEARD II, evaluated bimekizumab in adults with moderate to s...

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa PR Newswire Top-line results show that the two Phase 3 studies, BE HEARD I and BE HEARD II, met their primary and key secondary endpoints with statistical significance and consistent clinical re...

The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis PR Newswire Two articles report results from the Phase 3 BE OPTIMAL and BE COMPLETE studies evaluating bimekizumab, an investigational, selective inhibitor of IL-17A and IL-17F, in patient...

UCB to present data at the American Epilepsy Society 76th Annual Meeting 2022 supporting a decades-long commitment to transforming epilepsy care PR Newswire 21 scientific presentations, including 7 late breakers, showcase the breadth of UCB's portfolio, reinforcing commitment ...

Epilepsia Publishes Interim Results of Open-Label Extension Study of FINTEPLA® (fenfluramine) Oral Solution in Patients with Lennox-Gastaut Syndrome (LGS) PR Newswire Peer-reviewed results from the Phase 3 open-label extension study of FINTEPLA ® in LGS p...

UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients PR Newswire New drug application (NDA) for zilucoplan seeks approval for the treatment of generalized my...

Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis PR Newswire New late-breaking 52-week data from Phase 3 bimekizumab investigational studies ...

UCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022 PR Newswire Late-breaking 52-week data on investigational bimekizumab in the treatment of adults with active psoriatic arthritis and active axial spondy...